CL2012000278A1 - Proceso para la obtencion de derivados de 5-trifluorometil-pirimidinas; y uno de los compuestos intermediarios considerados. - Google Patents

Proceso para la obtencion de derivados de 5-trifluorometil-pirimidinas; y uno de los compuestos intermediarios considerados.

Info

Publication number
CL2012000278A1
CL2012000278A1 CL2012000278A CL2012000278A CL2012000278A1 CL 2012000278 A1 CL2012000278 A1 CL 2012000278A1 CL 2012000278 A CL2012000278 A CL 2012000278A CL 2012000278 A CL2012000278 A CL 2012000278A CL 2012000278 A1 CL2012000278 A1 CL 2012000278A1
Authority
CL
Chile
Prior art keywords
trifluoromethyl
pyrimidines
intermediate compounds
obtaining derivatives
compounds considered
Prior art date
Application number
CL2012000278A
Other languages
English (en)
Spanish (es)
Inventor
Guenter Linz
Gerd Kraemer
Sabrina Kusserow
Juergen Schnaubelt
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42712695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012000278(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2012000278A1 publication Critical patent/CL2012000278A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CL2012000278A 2009-08-14 2012-02-02 Proceso para la obtencion de derivados de 5-trifluorometil-pirimidinas; y uno de los compuestos intermediarios considerados. CL2012000278A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09167934 2009-08-14

Publications (1)

Publication Number Publication Date
CL2012000278A1 true CL2012000278A1 (es) 2012-10-12

Family

ID=42712695

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000278A CL2012000278A1 (es) 2009-08-14 2012-02-02 Proceso para la obtencion de derivados de 5-trifluorometil-pirimidinas; y uno de los compuestos intermediarios considerados.

Country Status (17)

Country Link
US (1) US8933227B2 (cg-RX-API-DMAC10.html)
EP (1) EP2464634B1 (cg-RX-API-DMAC10.html)
JP (1) JP5539519B2 (cg-RX-API-DMAC10.html)
KR (1) KR20120046248A (cg-RX-API-DMAC10.html)
CN (1) CN102471287A (cg-RX-API-DMAC10.html)
AR (1) AR077925A1 (cg-RX-API-DMAC10.html)
AU (1) AU2010283713A1 (cg-RX-API-DMAC10.html)
BR (1) BR112012002971A2 (cg-RX-API-DMAC10.html)
CA (1) CA2767965A1 (cg-RX-API-DMAC10.html)
CL (1) CL2012000278A1 (cg-RX-API-DMAC10.html)
EA (1) EA201200282A1 (cg-RX-API-DMAC10.html)
IL (1) IL217112A0 (cg-RX-API-DMAC10.html)
IN (1) IN2012DN01342A (cg-RX-API-DMAC10.html)
MX (1) MX2012001469A (cg-RX-API-DMAC10.html)
NZ (1) NZ597538A (cg-RX-API-DMAC10.html)
TW (1) TW201124385A (cg-RX-API-DMAC10.html)
WO (1) WO2011018518A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2718858A1 (en) * 2008-03-20 2009-09-24 Boehringer Ingelheim International Gmbh Selective synthesis of substituted pyrimidines
UY31714A (es) * 2008-03-20 2009-11-10 Boehringer Ingelheim Int Preparación selectiva de pirimidinas sustituidas
US8729265B2 (en) 2009-08-14 2014-05-20 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
CN102887860B (zh) * 2012-09-29 2015-07-01 上海泰坦科技有限公司 4-氯-6-三氟甲基嘧啶类化合物的制备方法
JP6391985B2 (ja) * 2014-05-16 2018-09-19 東ソー・ファインケム株式会社 2−置換−4−(2,2,2−トリフルオロエトキシ)−5−(トリフルオロメチル)ピリミジン誘導体及びその製造方法
JP6391988B2 (ja) * 2014-05-21 2018-09-19 東ソー・ファインケム株式会社 5−(トリフルオロメチル)ピリミジン誘導体の製造方法及び新規5−(トリフルオロメチル)ピリミジン誘導体
JP6262079B2 (ja) * 2014-06-02 2018-01-17 東ソー・ファインケム株式会社 4−(2,2,2−トリフルオロエトキシ)−5−(トリフルオロメチル)ピリミジン誘導体及びその製造方法
JP6431294B2 (ja) * 2014-06-16 2018-11-28 東ソー・ファインケム株式会社 5−(トリフルオロメチル)ピリミジン誘導体及びその製造法
JP6479486B2 (ja) * 2015-01-16 2019-03-06 東ソー・ファインケム株式会社 4−アルコキシ−5−(トリフルオロメチル)ピリミジン誘導体及びその製造方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6262A (ja) 1986-03-05 1987-01-06 Ishihara Sangyo Kaisha Ltd ベンゾイルウレア系化合物の製造方法
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
CA2463989C (en) 2001-10-17 2012-01-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof
DE10161763A1 (de) 2001-12-15 2003-07-17 Bayer Cropsience Ltd Neues herbizides Verfahren
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
WO2003095448A1 (en) 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
EA200500721A1 (ru) 2002-11-28 2005-12-29 Шеринг Акциенгезельшафт Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
GEP20084357B (en) 2002-12-20 2008-04-29 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
CN100465164C (zh) * 2003-09-05 2009-03-04 辉瑞产品公司 Cf3-取代嘧啶的选择性合成
MXPA06003054A (es) 2003-09-18 2006-05-31 Novartis Ag 2,4-di-(fenil-amino)-pirimidinas utiles en el tratamiento de trastornos proliferativos.
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
CN1953974A (zh) 2004-05-14 2007-04-25 辉瑞产品有限公司 治疗异常细胞生长的嘧啶衍生物
EP1598343A1 (de) 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
US7601714B2 (en) 2004-07-08 2009-10-13 Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of PKC-theta
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
WO2006074057A2 (en) 2004-12-30 2006-07-13 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
EP1705177A1 (en) 2005-03-23 2006-09-27 Schering Aktiengesellschaft N-aryl-sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents
WO2006117560A1 (en) 2005-05-05 2006-11-09 Astrazeneca Ab Pyrazolyl-amino- substituted pyrimidines and their use in the treatment of cancer
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20070032514A1 (en) 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
EP1945631B8 (en) 2005-10-28 2013-01-02 AstraZeneca AB 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
EP1966192B1 (en) 2005-12-01 2012-10-17 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
CA2634646C (en) 2005-12-21 2012-04-10 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
TW200804364A (en) 2006-02-22 2008-01-16 Boehringer Ingelheim Int New compounds
CA2648170A1 (en) 2006-04-10 2007-10-18 Boehringer Ingelheim International Gmbh 2, 4-diaminopyrimidine derivatives and their use for the treatment of cancer
AR060890A1 (es) 2006-05-15 2008-07-23 Boehringer Ingelheim Int Compuestos derivados de pirimidina y composicion farmaceutica en base a ellos
US8466318B2 (en) 2006-05-18 2013-06-18 Boehringer Ingelheim International Gmbh Method of preparing chiral cyclic β-aminocarboxamides
DE102006027156A1 (de) 2006-06-08 2007-12-13 Bayer Schering Pharma Ag Sulfimide als Proteinkinaseinhibitoren
CA2654670A1 (en) 2006-07-06 2008-01-10 Boehringer Ingelheim International Gmbh New compounds
DE102006041382A1 (de) 2006-08-29 2008-03-20 Bayer Schering Pharma Ag Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren
WO2008040951A1 (en) 2006-10-03 2008-04-10 Astrazeneca Ab Compounds
WO2008045978A1 (en) 2006-10-10 2008-04-17 Rigel Pharmaceuticals, Inc. Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors
WO2008046216A1 (en) 2006-10-18 2008-04-24 Methylgene, Inc. Kinase inhibitors and uses thereof
ES2381589T3 (es) 2006-10-19 2012-05-29 F. Hoffmann-La Roche Ag Aminometil-4-imidazoles
AR063527A1 (es) 2006-10-23 2009-01-28 Cephalon Inc Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores de alk y c-met
ES2550152T3 (es) 2006-12-13 2015-11-04 F. Hoffmann-La Roche Ag Derivados de 2-(piperidin-4-il)-4-fenoxi-o fenilamino-pirimidina como inhibidores no nucleósidos de transcriptasa inversa
EP2099771A1 (en) 2006-12-19 2009-09-16 Genentech, Inc. Pyrimidine kinase inhibitors
EP1939185A1 (de) 2006-12-20 2008-07-02 Bayer Schering Pharma Aktiengesellschaft Neuartige Hetaryl-Phenylendiamin-Pyrimidine als Proteinkinaseinhibitoren zur Behandlung von Krebs
WO2008079346A1 (en) 2006-12-21 2008-07-03 Vertex Pharmaceuticals Incorporated 5-cyan0-4- (pyrrolo [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
US20100144706A1 (en) 2006-12-22 2010-06-10 Boehringer Ingelheim International Gmbh Compounds
AR065015A1 (es) 2007-01-26 2009-05-13 Smithkline Beecham Corp Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer
US7947698B2 (en) 2007-03-23 2011-05-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
MX2009011090A (es) 2007-04-18 2009-11-02 Pfizer Prod Inc Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal.
AU2008275918B2 (en) 2007-07-17 2014-01-30 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as PKC inhibitors
WO2009017838A2 (en) 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
CA2696824A1 (en) 2007-08-28 2009-03-12 Irm Llc Compounds and compositions as kinase inhibitors
WO2009063240A1 (en) 2007-11-16 2009-05-22 Arrow Therapeutics Limited 2,4-diaminopyrimidine derivatives useful as inhibitors of aurora kinase
WO2009071535A1 (en) 2007-12-03 2009-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
WO2009079412A2 (en) 2007-12-14 2009-06-25 Ardea Biosciences Inc. Reverse transcriptase inhibitors
UY31714A (es) 2008-03-20 2009-11-10 Boehringer Ingelheim Int Preparación selectiva de pirimidinas sustituidas
CA2718858A1 (en) 2008-03-20 2009-09-24 Boehringer Ingelheim International Gmbh Selective synthesis of substituted pyrimidines
UY31929A (es) 2008-06-25 2010-01-05 Irm Llc Compuestos y composiciones como inhibidores de cinasa
CA2729546A1 (en) 2008-06-25 2009-12-30 Irm Llc Compounds and compositions as kinase inhibitors
RU2536584C2 (ru) 2008-06-27 2014-12-27 Авила Терапьютикс, Инк. Гетероарильные соединения и их применение
EP2179992A1 (de) 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
EP2179991A1 (de) 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
UY32240A (es) 2008-11-14 2010-06-30 Boeringer Ingelheim Kg Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
TW201024281A (en) 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
TWI491605B (zh) 2008-11-24 2015-07-11 Boehringer Ingelheim Int 新穎化合物
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
US8729265B2 (en) 2009-08-14 2014-05-20 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives

Also Published As

Publication number Publication date
EP2464634B1 (en) 2016-11-30
AU2010283713A1 (en) 2012-02-02
IN2012DN01342A (cg-RX-API-DMAC10.html) 2015-06-05
CA2767965A1 (en) 2011-02-17
AR077925A1 (es) 2011-10-05
IL217112A0 (en) 2012-02-29
US20110190499A1 (en) 2011-08-04
MX2012001469A (es) 2012-02-22
KR20120046248A (ko) 2012-05-09
JP2013501759A (ja) 2013-01-17
EP2464634A1 (en) 2012-06-20
CN102471287A (zh) 2012-05-23
NZ597538A (en) 2014-05-30
US8933227B2 (en) 2015-01-13
JP5539519B2 (ja) 2014-07-02
EA201200282A1 (ru) 2012-09-28
WO2011018518A1 (en) 2011-02-17
TW201124385A (en) 2011-07-16
BR112012002971A2 (pt) 2015-10-13

Similar Documents

Publication Publication Date Title
CL2012000278A1 (es) Proceso para la obtencion de derivados de 5-trifluorometil-pirimidinas; y uno de los compuestos intermediarios considerados.
SMT201600198B (it) Derivati di 1,2,4-triazina-4-ammina
CR20120295A (es) Triazolopiridinas
CL2016001732A1 (es) Métodos sintéticos para compuestos espiro-oxoindol (div. sol. 3633-13).
CR20110467A (es) Derivados de benzofuranilo como inhibidores de la glucoquinasa
CR20120334A (es) Derivados de imidazopiridina como inhibidores de jak
MX345552B (es) Compuestos heterocíclicos útiles para inhibición de cinasa.
ECSP12011654A (es) Derivados de 5-fluoropirimidinona
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
UY34472A (es) Derivados modificados de 4-fenil-piridina
DOP2014000033A (es) Aminoquinazolinas como inhibidores de quinasa
CL2008003095A1 (es) Procedeimiento de preparacion de dihidrotienopirimidas; uno de los compuestos intermediarios considerados; y el procedimiento de preparacion de dicho compuesto intermediario.
CR20130539A (es) Triazolopiridinas
CR20120637A (es) Triazolopiridinas sustituidas
ECSP11011245A (es) Novedosos herbicidas
CO6470820A2 (es) Espiro-epóxidos como productos intermedios
SMT201600076B (it) Derivati di 2-osso-1-pirrolidinil imidazotiadiazolo
HN2012000261A (es) Derivados de 5-fluoro-2-oxopirimidina-1(2h)-carboxilato
IT1393112B1 (it) Procedimento per la preparazione di derivati di prostaglandine
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
ECSP13012914A (es) Síntesis de derivados de 2-carboxamida-cicloamino-urea
DOP2012000260A (es) Uso de nuevos inhibidores de pan–cdk para tratar tumores
CY1121116T1 (el) Νεα μεθοδος για την συνθεση αγομελατινης
DK2403364T3 (da) Fremgangsmåde til fremstilling af opløsninger af astaxanthin-derivater
DK2493860T3 (da) Fremgangsmåde til fremstilling af 4-sulfinylpyrazolderivater